ALLMedicine Hemolytic Uremic Syndrome Center

May 23rd, 2020 - Ravulizumab, a new long-acting C5 inhibitor, recently received FDA approval for the treatment of aHUS. Rates of complete thrombotic microangiopathy response were similar to those observed in major eculizumab trials; however, fewer patients in the ...

May 21st, 2020 - Atypical hemolytic uremic syndrome (aHUS) can result in severe kidney dysfunction, secondary to thrombotic microangiopathy. Eculizumab has been used to treat this disorder, and has resulted in favourable outcomes in both, native and transplanted k...

May 13th, 2020 - The aim of this study was to investigate the histopathological findings in kidney biopsies in children with atypical hemolytic uremic syndrome (aHUS) and to determine whether specific pathological findings in aHUS have a prognostic value. Renal bi...

May 10th, 2020 - Recessive mutations in diacylglycerol kinase epsilon (DGKE) display genetic pleiotropy, with pathological features reported as either thrombotic microangiopathy or membranoproliferative glomerulonephritis (MPGN), and clinical features of atypical ...

May 3rd, 2020 - BACKGROUND Hemolytic uremic syndrome (HUS) can be categorized as primary (typical or atypical) or secondary (with a coexisting diseases). Typical HUS usually means shiga-toxin-medicated and thrombotic thrombocytopenic purpura. Secondary HUS is oft...

Apr 4th, 2019 - As of April 4, 2019, 72 people infected with the outbreak strain of E. coli O103 have been reported from five states. Eight people have been hospitalized. No cases of hemolytic uremic syndrome (HUS) or deaths have been reported.

Jul 16th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

Apr 10th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....

Aug 7th, 2014 - Guidelines for the management and investigation of hemolytic uremic syndrome.|2014|Igarashi T,Ito S,Sako M,Saitoh A,Hataya H,|standards,diagnosis,etiology,therapy,standards,

Dec 17th, 2013 - Atypical hemolytic uremic syndrome (aHUS) is rare and comprises the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Recently, abnormalities in the mechanisms underlying complement regulation have been focused...

May 23rd, 2020 - Ravulizumab, a new long-acting C5 inhibitor, recently received FDA approval for the treatment of aHUS. Rates of complete thrombotic microangiopathy response were similar to those observed in major eculizumab trials; however, fewer patients in the ...

May 21st, 2020 - Atypical hemolytic uremic syndrome (aHUS) can result in severe kidney dysfunction, secondary to thrombotic microangiopathy. Eculizumab has been used to treat this disorder, and has resulted in favourable outcomes in both, native and transplanted k...

May 13th, 2020 - The aim of this study was to investigate the histopathological findings in kidney biopsies in children with atypical hemolytic uremic syndrome (aHUS) and to determine whether specific pathological findings in aHUS have a prognostic value. Renal bi...

May 10th, 2020 - Recessive mutations in diacylglycerol kinase epsilon (DGKE) display genetic pleiotropy, with pathological features reported as either thrombotic microangiopathy or membranoproliferative glomerulonephritis (MPGN), and clinical features of atypical ...

May 3rd, 2020 - BACKGROUND Hemolytic uremic syndrome (HUS) can be categorized as primary (typical or atypical) or secondary (with a coexisting diseases). Typical HUS usually means shiga-toxin-medicated and thrombotic thrombocytopenic purpura. Secondary HUS is oft...

Oct 20th, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...

Oct 18th, 2019 - (Reuters) - The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc’s treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already been approved in the United States, Japan and th...

Jun 11th, 2019 - NEW YORK (Reuters Health) - The approval of the monoclonal antibody eculizumab for treatment of atypical hemolytic uremic syndrome led to significant improvements in outcomes, according to a study of French patients presented June 3 at American Tr...

Jun 5th, 2019 - Hemolytic uremic syndrome (HUS) is a rare illness that can be acquired through the consumption of food products contaminated with strains of Shiga toxin-producing Escherichia coli (E coli ; STEC). 1 Between 6% and 15% of individuals infected with.

Jun 1st, 2019 - Click here to access June 2019 Management of Neurologic Disorders in Federal Health Care Table of Contents Early and Accurate Identification of Parkinson Disease Among US Veterans Proton Pump Inhibitor Use and Risk of Dementia in the Veteran Popul.